Inicio
Resultado de la búsqueda
1 búsqueda de la palabra clave 'drug‐induced liver injury'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Differential characteristics in drug-induced autoimmune hepatitis / Juan Ignacio Marín Zuluaga ; Octavio Germán Muñoz Maya ; Óscar Mauricio Santos Sánchez ; Jorge Hernando Donado Gómez ; Juan Carlos Restrepo Gutiérrez
Título : Differential characteristics in drug-induced autoimmune hepatitis Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Óscar Mauricio Santos Sánchez, ; Jorge Hernando Donado Gómez, ; Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2018 Títulos uniformes : JGH Open Idioma : Inglés (eng) Palabras clave : Autoimmune hepatitis autoimmunity drug‐induced liver injury immunosuppression prognosis Resumen : Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH. Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016. Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P Mención de responsabilidad : Omar Yesid Martínez-Casas, Gabriel Sebastián Díaz-Ramírez, Juan Ignacio Marín-Zuluaga, Octavio Muñoz-Maya, Oscar Santos, Jorge Hernando Donado-Gómez, Juan Carlos Restrepo-Gutiérrez Referencia : JGH Open. 2018 May 24;2(3):97-104. DOI (Digital Object Identifier) : 10.1002/jgh3.12054 PMID : 30483571 Derechos de uso : CC BY-NC En línea : https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12054 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4143 Differential characteristics in drug-induced autoimmune hepatitis [documento electrónico] / Juan Ignacio Marín Zuluaga, ; Octavio Germán Muñoz Maya, ; Óscar Mauricio Santos Sánchez, ; Jorge Hernando Donado Gómez, ; Juan Carlos Restrepo Gutiérrez, . - 2018.
Obra : JGH Open
Idioma : Inglés (eng)
Palabras clave : Autoimmune hepatitis autoimmunity drug‐induced liver injury immunosuppression prognosis Resumen : Background and Aim: Drug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH. Methods: This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016. Results: A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P Mención de responsabilidad : Omar Yesid Martínez-Casas, Gabriel Sebastián Díaz-Ramírez, Juan Ignacio Marín-Zuluaga, Octavio Muñoz-Maya, Oscar Santos, Jorge Hernando Donado-Gómez, Juan Carlos Restrepo-Gutiérrez Referencia : JGH Open. 2018 May 24;2(3):97-104. DOI (Digital Object Identifier) : 10.1002/jgh3.12054 PMID : 30483571 Derechos de uso : CC BY-NC En línea : https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12054 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4143 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000756 AC-2018-043 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2018-043.pdfAdobe Acrobat PDF